{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:35:11Z","timestamp":1793435711734,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,22]],"date-time":"2027-09-22T00:00:00Z","timestamp":1821571200000},"content-version":"am","delay-in-days":325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA77598"],"award-info":[{"award-number":["P30 CA77598"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cct.2026.108478","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:30:43Z","timestamp":1789745443000},"page":"108478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Bayesian two-sample survival probability curves with comparative summary measures and sensitivity analyses"],"prefix":"10.1016","volume":"170","author":[{"given":"Michelle","family":"Leeberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghua","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2026.108478_bb0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/annonc\/mdy462","article-title":"Interpretation of time-to-event outcomes in randomized trials: an online randomized experiment","volume":"30","author":"Weir","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cct.2026.108478_bb0010","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/pst.1917","article-title":"Treatment effect quantification for time-to-event endpoints\u2013estimands, analysis strategies, and beyond","volume":"18","author":"Rufibach","year":"2019","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.cct.2026.108478_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.106707","article-title":"Two-sample survival probability curves: a graphical approach for the analysis of time to event data in clinical trials","volume":"115","author":"Castro-Pearson","year":"2022","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.cct.2026.108478_bb0020","first-page":"831","article-title":"The two sample problem with censored data","volume":"4","author":"Efron","year":"1967","journal-title":"Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability"},{"key":"10.1016\/j.cct.2026.108478_bb0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1081\/SAC-120017495","article-title":"Two-sample comparisons with the Efron-test under random censorship","volume":"32","author":"Frick","year":"2003","journal-title":"Communications in Statistics - Simulation and Computation"},{"key":"10.1016\/j.cct.2026.108478_bb0030","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/sim.4154","article-title":"On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data","volume":"30","author":"Uno","year":"2011","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2026.108478_bb0035","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","article-title":"Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors","volume":"15","author":"Harrell","year":"1996","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2026.108478_bb0040","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1093\/biomet\/92.4.965","article-title":"Concordance probability and discriminatory power in proportional hazards regression","volume":"92","author":"G\u00f6nen","year":"2005","journal-title":"Biometrika"},{"key":"10.1016\/j.cct.2026.108478_bb0045","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1177\/0962280216680245","article-title":"Use of the concordance index for predictors of censored survival data","volume":"27","author":"Brentnall","year":"2018","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.cct.2026.108478_bb0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12874-022-01679-6","article-title":"Survival prediction models: an introduction to discrete-time modeling","volume":"22","author":"Suresh","year":"2022","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.cct.2026.108478_bb0055","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/ckj\/sfad057","article-title":"A pre-transplantation risk assessment tool for graft survival in Dutch pediatric kidney recipients","volume":"16","author":"Oomen","year":"2023","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.cct.2026.108478_bb0060","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1214\/20-BA1229","article-title":"Robust adaptive incorporation of historical control data in a randomized trial of external cooling to treat septic shock","volume":"16","author":"Murray","year":"2021","journal-title":"Bayesian Anal."},{"key":"10.1016\/j.cct.2026.108478_bb0065","first-page":"155","article-title":"It\u2019s about time: using discrete-time survival analysis to study duration and the timing of events","volume":"18","author":"Singer","year":"1993","journal-title":"J. Educ. Stat."},{"key":"10.1016\/j.cct.2026.108478_bb0070","article-title":"Restricted win probability with Bayesian estimation for implementing the estimand framework in clinical trials with a time-to-event outcome","author":"Leeberg","year":"2024","journal-title":"ArXiv"},{"key":"10.1016\/j.cct.2026.108478_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111340","article-title":"Restricted net treatment benefit in oncology","volume":"170","author":"Piffoux","year":"2024","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.cct.2026.108478_bb0080","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc. B. Methodol."},{"key":"10.1016\/j.cct.2026.108478_bb0085","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1002\/sim.3292","article-title":"The generalized F distribution: an umbrella for parametric survival analysis","volume":"27","author":"Cox","year":"2008","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2026.108478_bb0090","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/biostatistics\/kxac009","article-title":"A flexible parametric accelerated failure time model and the extension to time-dependent acceleration factors","volume":"24","author":"Crowther","year":"2022","journal-title":"Biostatistics"},{"key":"10.1016\/j.cct.2026.108478_bb0095","series-title":"Bayesian Survival Analysis","author":"Ibrahim","year":"2010"},{"key":"10.1016\/j.cct.2026.108478_bb0100","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2307\/2533573","article-title":"Validity and efficiency of approximation methods for tied survival times in Cox regression","volume":"53","author":"Hertz-Picciotto","year":"1997","journal-title":"Biometrics"},{"key":"10.1016\/j.cct.2026.108478_bb0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/1467-9868.00374","article-title":"Thin plate regression splines","volume":"65","author":"Wood","year":"2003","journal-title":"J. R. Stat. Soc."},{"key":"10.1016\/j.cct.2026.108478_bb0110","author":"Castro-Pearson"},{"key":"10.1016\/j.cct.2026.108478_bb0115","author":"Wood"},{"key":"10.1016\/j.cct.2026.108478_bb0120","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.cct.2026.108478_bb0125","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.cct.2026.108478_bb0130","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1093\/annonc\/mdv130","article-title":"Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial","volume":"26","author":"Passardi","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.cct.2026.108478_bb0135","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.cct.2026.108478_bb0140","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.cct.2026.108478_bb0145","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2015.64.2488","article-title":"Comparison of treatment effects measured by the hazard ratio and by the ratio of restricted mean survival times in oncology randomized controlled trials","volume":"34","author":"Trinquart","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2026.108478_bb0150","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.1200\/JCO.19.01681","article-title":"Methods for accommodating nonproportional hazards in clinical trials: ready for the primary analysis?","volume":"37","author":"Freidlin","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cct.2026.108478_bb0155","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1002\/sim.9444","article-title":"Versatile tests for window mean survival time","volume":"41","author":"Paukner","year":"2022","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2026.108478_bb0160","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1177\/1740774520905563","article-title":"Designing clinical trials with (restricted) mean survival time endpoint: practical considerations","volume":"17","author":"Eaton","year":"2020","journal-title":"Clin. Trials"},{"key":"10.1016\/j.cct.2026.108478_bb0165","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J. R. Stat. Soc. Series B Stat. Methodology"},{"key":"10.1016\/j.cct.2026.108478_bb0170","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1002\/sim.2836","article-title":"Parametric survival analysis and taxonomy of hazard functions for the generalized gamma distribution","volume":"26","author":"Cox","year":"2007","journal-title":"Stat. Med."},{"key":"10.1016\/j.cct.2026.108478_bb0175","author":"Baio"},{"key":"10.1016\/j.cct.2026.108478_bb0180","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.cct.2026.108478_bb0185","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.cct.2026.108478_bb0190","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41241-018-0067-7","article-title":"Use of interval-censored survival data as an alternative to Kaplan-Meier survival curves: studies of oral lesion occurrence in liver transplants and cancer recurrence","volume":"38","author":"Rodrigues","year":"2018","journal-title":"Appl. Cancer Res."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426002648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714426002648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T08:17:19Z","timestamp":1793434639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714426002648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":38,"alternative-id":["S1551714426002648"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2026.108478","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bayesian two-sample survival probability curves with comparative summary measures and sensitivity analyses","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2026.108478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108478"}}